SI2200621T1 - Postopki, farmacevtski sestavki in izdelani proizvodi za dajanje terapevtskih celic živalskemu centralnemu živčnemu sistemu - Google Patents

Postopki, farmacevtski sestavki in izdelani proizvodi za dajanje terapevtskih celic živalskemu centralnemu živčnemu sistemu

Info

Publication number
SI2200621T1
SI2200621T1 SI200830702T SI200830702T SI2200621T1 SI 2200621 T1 SI2200621 T1 SI 2200621T1 SI 200830702 T SI200830702 T SI 200830702T SI 200830702 T SI200830702 T SI 200830702T SI 2200621 T1 SI2200621 T1 SI 2200621T1
Authority
SI
Slovenia
Prior art keywords
cns
methods
articles
manufacture
pharmaceutical compositions
Prior art date
Application number
SI200830702T
Other languages
English (en)
Slovenian (sl)
Inventor
Ii William H Frey
Lusine Danielyan
Christoph H Gleiter
Original Assignee
Ii William H Frey
Lusine Danielyan
Christoph H Gleiter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ii William H Frey, Lusine Danielyan, Christoph H Gleiter filed Critical Ii William H Frey
Publication of SI2200621T1 publication Critical patent/SI2200621T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
SI200830702T 2007-09-11 2008-09-04 Postopki, farmacevtski sestavki in izdelani proizvodi za dajanje terapevtskih celic živalskemu centralnemu živčnemu sistemu SI2200621T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97128407P 2007-09-11 2007-09-11
US12/109,066 US8283160B2 (en) 2007-09-11 2008-04-24 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
PCT/US2008/075223 WO2009035901A1 (en) 2007-09-11 2008-09-04 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP08831016A EP2200621B1 (en) 2007-09-11 2008-09-04 Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Publications (1)

Publication Number Publication Date
SI2200621T1 true SI2200621T1 (sl) 2012-09-28

Family

ID=40432083

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830702T SI2200621T1 (sl) 2007-09-11 2008-09-04 Postopki, farmacevtski sestavki in izdelani proizvodi za dajanje terapevtskih celic živalskemu centralnemu živčnemu sistemu

Country Status (24)

Country Link
US (3) US8283160B2 (https=)
EP (1) EP2200621B1 (https=)
JP (2) JP5600294B2 (https=)
KR (2) KR101504110B1 (https=)
CN (2) CN101801397A (https=)
AT (1) ATE554778T1 (https=)
AU (1) AU2008299124B2 (https=)
BR (1) BRPI0816325B8 (https=)
CA (1) CA2696892C (https=)
CR (1) CR11304A (https=)
CY (1) CY1113120T1 (https=)
DK (1) DK2200621T3 (https=)
ES (1) ES2388403T3 (https=)
HR (1) HRP20120560T1 (https=)
IL (1) IL204371A (https=)
MX (1) MX2010002738A (https=)
MY (1) MY154061A (https=)
PL (1) PL2200621T3 (https=)
PT (1) PT2200621E (https=)
RU (1) RU2468818C2 (https=)
SG (1) SG184724A1 (https=)
SI (1) SI2200621T1 (https=)
UA (1) UA98507C2 (https=)
WO (1) WO2009035901A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518390B2 (en) * 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2153844A1 (en) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Human hyaluronidases for axonal regrowth
KR20200011604A (ko) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
US9821149B2 (en) * 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
EP2794854B1 (en) 2011-12-23 2018-06-20 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
US20130336928A1 (en) * 2012-06-18 2013-12-19 Healthpartners Research & Education Methods and pharmaceutical compositions for treatment of central nervous system disorders with therapeutic agent(s) in patients with concurrent non-cns condition(s) or disorders contraindicating systemic administration of the therapeutic agent(s)
FR3001974B1 (fr) 2013-02-08 2016-02-12 Olivier Schussler Procede de purification de cellules
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
US10279012B2 (en) * 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015134869A2 (en) * 2014-03-06 2015-09-11 Children's National Medical Center Treatment of neonatal brain injury with hb-egf
EP3174584B1 (en) * 2014-07-29 2022-05-04 Edenhoffer, Peter Positive pressure inspiration device for delivery of medicaments
US11413408B2 (en) 2014-07-29 2022-08-16 Peter Edenhoffer Positive pressure inspiration device for delivery of medicaments
US10130657B2 (en) 2015-02-13 2018-11-20 John C. Hughes Formulation, apparatus, and methods for treatment of brain trauma
US10335435B2 (en) 2015-05-22 2019-07-02 Marco Merida Method for endoscopically delivering stem cells to the brain using an intranasal, injectable approach
US20160361253A1 (en) * 2015-06-13 2016-12-15 Noveome Biotherapeutics, Inc. Novel Methods for Delivering Therapeutic Agents to the Eye via Nasal Passages
WO2017011326A1 (en) 2015-07-10 2017-01-19 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
ES2938089T3 (es) 2015-08-13 2023-04-04 Takeda Pharmaceuticals Co Tubos de extracción de sangre al vacío que contienen inhibidores de proteasa para la evaluación de la activación del sistema de contacto
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
CN106924286A (zh) * 2017-02-16 2017-07-07 上海安集协康生物技术股份有限公司 一种经鼻腔给药用于帕金森病治疗的神经干细胞制剂
CN108732355B (zh) * 2017-04-25 2021-06-25 首都医科大学附属北京安定医院 一种测定bace1酶切nrg1活性的检测方法及其试剂盒
US20190060109A1 (en) * 2017-08-31 2019-02-28 Gregory Todd Johnson Method of Preventing Traumatic Brain Injury (TBI)
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
CN108096280A (zh) * 2017-12-28 2018-06-01 上海安集协康生物技术股份有限公司 一种神经干细胞滴鼻剂
KR20220005900A (ko) * 2020-07-07 2022-01-14 가톨릭대학교 산학협력단 뇌신경계질환 예방 또는 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
ES2252993T3 (es) * 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US20020169102A1 (en) * 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
JP3886346B2 (ja) * 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
EP1438942A1 (en) * 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
WO2005056755A2 (en) * 2003-12-02 2005-06-23 Catholic Healthcare West Compositions and methods for propagation of neural progenitor cells
WO2007002664A2 (en) * 2005-06-22 2007-01-04 Massachusetts Institute Of Technology Propagation of undifferentiated embryonic stem cells in hyaluronic acid hydrogel
US9456979B2 (en) * 2006-04-27 2016-10-04 Sri International Adminstration of intact mammalian cells to the brain by the intranasal route
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system

Also Published As

Publication number Publication date
AU2008299124B2 (en) 2013-07-04
MY154061A (en) 2015-04-30
UA98507C2 (ru) 2012-05-25
CY1113120T1 (el) 2016-04-13
CA2696892C (en) 2016-05-17
HRP20120560T1 (hr) 2012-08-31
AU2008299124A1 (en) 2009-03-19
EP2200621B1 (en) 2012-04-25
US9445991B2 (en) 2016-09-20
RU2468818C2 (ru) 2012-12-10
PL2200621T3 (pl) 2012-10-31
ES2388403T3 (es) 2012-10-15
EP2200621A4 (en) 2011-03-16
MX2010002738A (es) 2010-08-04
BRPI0816325B1 (pt) 2020-04-22
WO2009035901A1 (en) 2009-03-19
DK2200621T3 (da) 2012-08-06
US20090068155A1 (en) 2009-03-12
SG184724A1 (en) 2012-10-30
CN101801397A (zh) 2010-08-11
BRPI0816325B8 (pt) 2021-05-25
CA2696892A1 (en) 2009-03-19
US8283160B2 (en) 2012-10-09
US20130028874A1 (en) 2013-01-31
PT2200621E (pt) 2012-07-31
US20160206554A1 (en) 2016-07-21
CN103181932A (zh) 2013-07-03
KR20100094450A (ko) 2010-08-26
JP5600294B2 (ja) 2014-10-01
CR11304A (es) 2010-05-03
IL204371A (en) 2015-02-26
JP2014098051A (ja) 2014-05-29
BRPI0816325A2 (pt) 2015-03-24
ATE554778T1 (de) 2012-05-15
RU2010113932A (ru) 2011-10-20
KR101504110B1 (ko) 2015-03-19
KR20150039197A (ko) 2015-04-09
JP2010539084A (ja) 2010-12-16
EP2200621A1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
MY154061A (en) Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
WO2009001359A3 (en) Compositions and methods for inhibiting expression of pro-apoptotic genes
WO2012103038A9 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2012070015A9 (en) Inhibitors of the activity of complex iii of the mitochondrial electron transport chain and use thereof for treating diseases
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2012054535A3 (en) Compounds, compositions and methods useful for cholesterol mobilisation
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
JO3089B1 (ar) مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2011025706A3 (en) Heterocyclic amide compounds as protein kinase inhibitors
CL2012003450A1 (es) Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc.
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
CA2881554C (en) Methods for inhibiting fascin
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2009045053A3 (en) A cancer sensitizer comprising chlorogenic acid
MX336278B (es) Composiciones y metodos para la prevencion y el tratamiento de heridas.
WO2007120930A3 (en) Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
MX2010004859A (es) Nueva composicion para tratar los efectos secundarios del tratamiento anticanceroso.
MX2009010384A (es) Derivados de quinolina y composiciones farmaceuticas que los comprenden para la inhibicion de selectinas.
WO2011094208A3 (en) Methods and pharmaceutical compositions for preventing and treating renal impairment